专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

131. 发明授权

US09592251B2 Multi-vinylsulfone containing molecule 有权
标题翻译：含有多乙烯基砜的分子
公开(公告)号：US09592251B2
公开(公告)日：2017-03-14
申请号：US14126725
申请日：2012-06-15
申请人： Ying Chau , Yu Yu
发明人： Ying Chau , Yu Yu
IPC分类号： A61K9/14 , A61K39/29 , A61K31/74 , A61K31/715 , A61K31/795 , A61K31/573 , C07K16/22 , A61K31/10 , A61K31/721 , A61K31/728 , A61K31/734
CPC分类号： A61K31/795 , A61K31/10 , A61K31/573 , A61K31/721 , A61K31/728 , A61K31/734 , C07K16/22
摘要： A multi-vinylsulfone containing molecule is described herein. The multi-vinylsulfone containing molecule can be formed by dissolving a water soluble polymer containing a hydroxyl group in an aqueous solution to form a polymer solution; adding a molecule containing two vinylsulfone groups to the polymer solution; and forming a modified polymer by controlling a number of the vinylsulfone groups that are added to the polymer. A hydrogel is also described herein that can include the multi-vinylsulfone containing molecule and a multi-thiol containing molecule. The hydrogel can be formed from an aqueous solution that includes the multi-vinylsulfone containing molecule and the multi-thiol containing molecule by undergoing gelatation upon delivery to a site in the body. Also described is a drug delivery system that employs the hydrogel.
摘要翻译：本文描述了含有多乙烯基砜的分子。含有多乙烯基砜的分子可以通过将含有羟基的水溶性聚合物溶解在水溶液中形成聚合物溶液而形成; 向聚合物溶液中加入含有乙烯基砜基团的分子; 以及通过控制添加到聚合物中的数量的乙烯基砜基来形成改性聚合物。本文还描述了可以包括含有多乙烯基砜的分子和含多硫醇的分子的水凝胶。水凝胶可以由含有多乙烯基砜的分子和含多硫醇的分子的水溶液形成，通过在递送到体内的部位时经历凝胶化。还描述了采用水凝胶的药物递送系统。

132. 发明授权

US09592248B2 Prebiotic formulations and methods of use 有权
标题翻译：益生元配方及使用方法
公开(公告)号：US09592248B2
公开(公告)日：2017-03-14
申请号：US14860233
申请日：2015-09-21
申请人： Ritter Pharmaceuticals, Inc.
发明人： Andrew J. Ritter , Dennis Savaiano , David Barnes , Todd Klaenhammer
IPC分类号： C12P19/04 , A61K31/702 , A61K31/715 , A61K35/742 , A61K35/744 , A61K9/48
CPC分类号： A61K31/702 , A23L33/10 , A23L33/135 , A23L33/21 , A23V2002/00 , A61K9/4825 , A61K9/4891 , A61K31/715 , A61K35/742 , A61K35/744 , Y02A50/473 , A61K2300/00 , A23V2200/3202 , A23V2250/28
摘要： The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and pharmaceutical compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a pharmaceutical composition comprising a prebiotic, optionally in combination with effective amount of a probiotic microbe or microbes.
摘要翻译：本发明提供了用于治疗与乳糖不耐症有关的症状和胃肠健康的总体改善的方法和药物组合物。本文描述的是通过向有需要的受试者施用包含益生元的药物组合物，任选地与有效量的益生菌微生物或微生物组合，来改善整体胃肠健康或降低乳糖不耐症的症状的方法和药物组合物。

133. 发明授权

US09579340B2 Prebiotic formulations and methods of use 有权
标题翻译：益生元配方及使用方法
公开(公告)号：US09579340B2
公开(公告)日：2017-02-28
申请号：US14846449
申请日：2015-09-04
申请人： Ritter Pharmaceuticals, Inc.
发明人： Andrew J. Ritter , Dennis Savaiano , David Barnes , Todd Klaenhammer
IPC分类号： C12P19/04 , A61K31/715 , A61K31/702 , A61K35/745 , A61K35/747 , A61K31/7016 , A61K35/741 , A61K9/48
CPC分类号： A61K31/715 , A23L33/135 , A23L33/21 , A23V2002/00 , A23Y2220/00 , A23Y2300/00 , A61K9/4825 , A61K31/7004 , A61K31/7016 , A61K31/702 , A61K35/741 , A61K35/745 , A61K35/747 , Y02A50/473 , A61K2300/00 , A23V2200/32 , A23V2200/3202 , A23V2200/3204
摘要： The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes.
摘要翻译：本发明提供了用于治疗与乳糖不耐症有关的症状以及胃肠健康的总体改善的方法和组合物。本文描述的是通过向有需要的受试者施用益生元组合物，任选地与有效量的益生菌微生物或微生物组合，来改善整体胃肠健康或降低乳糖不耐症的症状的方法和组合物。

134. 发明授权

US09555133B2 Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents 有权
标题翻译：多元醇和聚醚氧化铁络合物作为药理学和/或MRI造影剂
公开(公告)号：US09555133B2
公开(公告)日：2017-01-31
申请号：US13937923
申请日：2013-07-09
申请人： AMAG Pharmaceuticals, Inc.
发明人： Ernest V. Groman , Kenneth G. Paul , Timothy B. Frigo , Howard Bengele , Jerome M. Lewis
IPC分类号： A61B5/055 , A01N43/04 , A61K31/715 , A61K49/12 , A61K47/48 , A61K49/18 , B82Y5/00 , A61K9/14 , A61K33/26 , A61K47/36
CPC分类号： A61K49/126 , A61K9/14 , A61K31/721 , A61K33/26 , A61K47/36 , A61K47/6923 , A61K47/6929 , A61K49/186 , A61K49/1863 , B82Y5/00
摘要： Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran. The complex is stable to terminal sterilization by autoclaving. The compositions are suitable for parenteral administration to a subject for the treatment of iron deficiencies or as MRI contrast agent. The complex is substantially immunosilent, provide minimal anaphylaxis and undergo minimal dissolution in vivo. The pharmacological compositions of the complex contain minimal free iron which can be quantified by a variety of methods.
摘要翻译：公开了氧化铁络合物，药物组合物和单位剂量及其施用方法，其使用与多元醇的氧化铁络合物。药物组合物使用多糖氧化铁络合物，其中多糖是改性多元醇，例如羧基烷基化还原葡聚糖。复合物通过高压灭菌对终端灭菌稳定。该组合物适用于对受试者的肠胃外给药以治疗铁缺乏症或作为MRI造影剂。复合物基本上是免疫安全的，提供最小的过敏反应，并在体内经历最小的溶解。复合物的药物组成含有最小的游离铁，可以通过各种方法进行定量。

135. 发明申请

US20160361343A1 SEPSIS TREATMENT AND RELATED COMPOSITIONS METHODS AND SYSTEMS 审中-公开
标题翻译： SEPSIS治疗和相关组合物的方法和系统
公开(公告)号：US20160361343A1
公开(公告)日：2016-12-15
申请号：US15179810
申请日：2016-06-10
申请人： California Institute of Technology
发明人： Sarkis K. MAZMANIAN , June L. Round , Yue Shen
IPC分类号： A61K31/715 , A61K45/06 , A61K9/00
CPC分类号： A61K31/715 , A61K9/0019 , A61K45/06
摘要： Provided herein are methods and systems and related compositions comprising an effective amount of one or more zwitterionic polysaccharide possibly in combination with one or more antibiotics, for treatment and/or prevention of sepsis or a condition associated thereto in an individual.
摘要翻译：本文提供的方法和系统和相关组合物包含有效量的一种或多种两性离子多糖，可能与一种或多种抗生素组合，用于治疗和/或预防败血症或与个体相关的病症。

136. 发明申请

US20160361255A1 Peptide Nanotubes for Slow Release of Drugs at Peripheral Nerve Injury 审中-公开
标题翻译：用于缓解周围神经损伤药物的肽纳米管
公开(公告)号：US20160361255A1
公开(公告)日：2016-12-15
申请号：US15177672
申请日：2016-06-09
申请人： The University of Toledo
发明人： Joshua Park , Dong Shik Kim , Nicholas Chiaia
IPC分类号： A61K9/00 , A61K31/715 , A61K47/18
CPC分类号： A61K9/0092 , A61K31/715 , A61K47/34
摘要： Described herein are materials and methods useful for the treatment of neurodegenerative disorders in a subject. Materials described herein include polysaccharide digestive products resulting from the enzymatic hydrolysis of low acyl gellan gum.
摘要翻译：本文描述了可用于治疗受试者中的神经变性疾病的材料和方法。本文所述的材料包括由低酰基结耳喃胶的酶水解产生的多糖消化产物。

137. 发明授权

US09518975B2 Alpha-keto-isovalerate as a biomarker of prebiotic efficacy for weight gain prevention 有权
标题翻译： α-酮 - 异戊酸酯作为增益预防的益生元效能的生物标志物
公开(公告)号：US09518975B2
公开(公告)日：2016-12-13
申请号：US14774655
申请日：2014-03-13
申请人： Nestec S.A.
发明人： Francois-Pierre Martin , Sebastiano Collino , Ivan Montoliu Roura
IPC分类号： G01N33/493 , G01N33/50 , A61K31/733 , A61K31/715 , G01N33/68 , G01N24/08
CPC分类号： G01N33/493 , A61K31/715 , A61K31/733 , C12Q2565/633 , G01N24/08 , G01N33/50 , G01N33/6893 , G01N2570/00 , G01N2800/044 , G01N2800/50 , G01N2800/52 , G01N2800/70
摘要： The present invention relates generally to the field of nutrition and health, particular, the present invention relates to alpha-keto-isovalerate as a biomarker urine of the efficacy of prebiotics for the prevention of diet induced weight gain.
摘要翻译：本发明一般涉及营养和健康领域，特别地，本发明涉及α-酮 - 异戊酸酯作为益生元用于预防饮食诱导体重增加的功效的生物标志物尿。

138. 发明申请

US20160354323A1 NUTRITIONAL COMPOSITIONS CONTAINING AN ELEVATED LEVEL OF INOSITOL AND USES THEREOF 审中-公开
标题翻译：营养组合物含有高度的INOSITOL及其用途
公开(公告)号：US20160354323A1
公开(公告)日：2016-12-08
申请号：US14729132
申请日：2015-06-03
申请人： Mead Johnson Nutrition Company
发明人： Chenzhong Kuang , Yan Xiao , Colin Rudolph , Dirk Hondmann
IPC分类号： A61K31/047 , A23L1/29 , A61K47/12 , A61K31/715 , A61K47/26 , A61K47/42
CPC分类号： A61K31/047 , A23L33/40 , A23V2002/00 , A23V2200/322 , A23V2250/641 , A61K31/715 , A61K47/12 , A61K47/26 , A61K47/42
摘要： A method for enhancing neurological health and development in a subject involving administering to the subject a nutritional composition including no greater than about 7 g/100 kcal of a fat or lipid source; no greater than about 7 g/100 kcal of a protein or protein equivalent source; at least about 5 g/100 kcal of a carbohydrate; and at least about 9 mg/100 kcal of inositol, wherein the ratio of exogenous inositol to inherent inositol is at least 50:50.
摘要翻译：一种用于增强受试者的神经系统健康和发育的方法，包括对受试者施用不超过约7g / 100kcal脂肪或脂质来源的营养组合物; 不大于约7g / 100kcal的蛋白质或蛋白质当量源; 至少约5g / 100kcal的碳水化合物; 和至少约9mg / 100kcal的肌醇，其中外源肌醇与固有肌醇的比例为至少50:50。

139. 发明授权

US09487596B2 Compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient 有权
标题翻译：从喹诺酮分离的化合物，以及用于预防或治疗含有该化合物作为活性成分的糖尿病的组合物
公开(公告)号：US09487596B2
公开(公告)日：2016-11-08
申请号：US14239136
申请日：2012-06-28
申请人： Bong Hyun Chung , So Yeon Yi , Ui Jin Lee
发明人： Bong Hyun Chung , So Yeon Yi , Ui Jin Lee
IPC分类号： C07H15/04 , C08B37/00 , A61K36/39 , C07D407/12 , C07D407/14 , A23L1/29 , A61K31/715 , A61K45/06 , A61K31/351
CPC分类号： C08B37/006 , A23L33/40 , A61K31/351 , A61K31/715 , A61K36/39 , A61K45/06 , C07D407/12 , C07D407/14 , C07H15/04
摘要： The present invention relates to a novel compound isolated from Quamoclit sp., and more particularly to a novel compound isolated from Quamoclit sp. and a composition for preventing or treating diabetes and its complications comprising the compound as an active ingredient. The novel compound isolated from Quamoclit sp. according to the present invention has excellent effects on lowering blood sugar, promoting insulin secretion, inhibiting VEGF expression, and so on. Thus, the present invention not only functions to prevent or treat diabetes and its complications, but also functions to promote treatment effects when treated together with conventional diabetes medicines.
摘要翻译：本发明涉及从Quamoclit sp。分离的新化合物，更具体地说涉及从Quamoclit sp。分离的新型化合物。以及用于预防或治疗糖尿病及其并发症的组合物，其包含该化合物作为活性成分。从Quamoclit sp。根据本发明对降低血糖，促进胰岛素分泌，抑制VEGF表达等具有优异的效果。因此，本发明不仅起到预防或治疗糖尿病及其并发症的作用，而且还用于与常规糖尿病药物一起治疗时促进治疗效果的功能。

140. 发明申请

US20160263144A1 COMPOSITION & METHODS OF SCREENING 审中-公开
标题翻译：组合物和筛选方法
公开(公告)号：US20160263144A1
公开(公告)日：2016-09-15
申请号：US15034420
申请日：2014-11-05
申请人： OPTIBIOTIX LIMITED
发明人： Stephen Patrick O'HARA , Robert RASTALL
IPC分类号： A61K31/715 , C12Q1/02 , A61K49/00 , A61K9/50 , A61K9/00
CPC分类号： A61K31/715 , A23L29/269 , A23L33/135 , A23L33/26 , A23V2002/00 , A23Y2220/00 , A23Y2220/35 , A23Y2220/71 , A61K9/0053 , A61K9/50 , A61K35/741 , A61K45/06 , A61K49/0004 , C12Q1/025 , G01N2333/335 , G01N2333/938 , G01N2500/10 , A23V2200/3202 , A23V2200/3204 , A23V2200/328 , A23V2250/28 , A61K2300/00
摘要： The present invention relates to a prebiotic composition comprising a microbially produced oligosaccharide, wherein the oligosaccharide is characterised by being selective for a pre-determined probiotic bacterial strain and also capable of being produced by the pre-determined probiotic bacteria by reverse enzyme action. The present invention also relates to methods of screening a composition suitable for use as a prebiotic and methods for screening of prebiotics for incorporation into synbiotic formulations.
摘要翻译：本发明涉及包含微生物产生的寡糖的益生元组合物，其中寡糖的特征在于对预定的益生菌菌株是选择性的，并且还能够通过反向酶作用由预定的益生菌生产。本发明还涉及筛选适合用作益生元的组合物的方法以及用于筛选益生元以掺入合生素制剂的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式